Nivolumab plus brentuximab vedotin for relapsed/refractory diffuse large B-cell lymphoma
Overall, the efficacy data from CheckMate 436 do not support the use of nivolumab plus BV for the treatment of R/R DLBCL.
Publications
1 shownFrequent Co-Authors
Researcher Info
- h-index
- 0
- Publications
- 1
- Citations
- 0
- Institution
- Princess Margaret Cancer Centre
External Links
Identifiers
- ORCID
- 0000-0002-6117-320X
Impact Metrics
h-index
0
h-index: Number of publications with at least h citations each.